Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib

被引：0
|
作者：
Hua Cheng
She-Juan An
Song Dong
Yi-Fang Zhang
Xu-Chao Zhang
Zhi-Hong Chen
Yi-Long Jian-Su
机构：
[1] Guangdong Lung Cancer Institute; Medical Research Center of Guangdong General Hospital & Guangdong Academy of Medical Sciences,
[2] Thoracic oncology,undefined
[3] the fifth affiliated hospital of Sun Yat-Sen university,undefined
来源：
Journal of Hematology & Oncology | / 4卷
关键词：
Paclitaxel; Gefitinib; Erlotinib; H1650 Cell; Combination Index;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer
    Soo, Ross A.
    Kim, Hye Ryun
    Asuncion, Bernadette Reyna
    Fazreen, Zul
    Omar, Mohamed Feroz Mohd
    Herrera, Maria Cynthia
    Lim, Joey Sze Yun
    Sia, Grace
    Soong, Richie
    Cho, Byoung-Chul
    LUNG CANCER, 2017, 105 : 17 - 22
  • [32] De novo MET amplification in EGFR-mutant non-small cell lung cancer
    Lee, D. D. W.
    Wang, L.
    Lai, G.
    Lim, T. K. H.
    Tan, D. S. W.
    ANNALS OF ONCOLOGY, 2024, 35 : S1649 - S1650
  • [33] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
    Ortega-Franco, Ana
    Rafee, Shereen
    ONCOLOGY AND THERAPY, 2022, 10 (01) : 13 - 22
  • [34] Neurological death in patients with EGFR-mutant non-small cell lung cancer.
    Ramotar, Matthew
    Barnes, Sierra
    Doherty, Mark
    Shultz, David Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] EGFR-mutant non-small cell lung cancer in Aberdeen, Scotland - Treatment and outcomes
    El-Shakankery, K.
    Steven, E.
    Clark, C.
    Stilwell, C.
    Kerr, K.
    Nicolson, M.
    LUNG CANCER, 2017, 103 : S35 - S36
  • [36] CARDIOVASCULAR EVENTS IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER ON OSIMERTINIB
    Peleg, Ariel
    Ibtida, Ishmam
    Liu, Jennifer
    Steingart, Richard
    Yu, Anthony
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 3288 - 3288
  • [37] Serum EGFR in patients with non-small cell lung cancer (NSCLC) treated with gefitinib
    Spreafico, A
    Gregorc, V
    Ludovini, V
    Pistola, L
    Amoroso, M
    Tofanetti, F
    Compagnoni, A
    Aondio, G
    Tonato, M
    Villa, E
    LUNG CANCER, 2005, 49 : S112 - S113
  • [38] Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
    Chmielecki, Juliann
    Foo, Jasmine
    Oxnard, Geoffrey R.
    Hutchinson, Katherine
    Ohashi, Kadoaki
    Somwar, Romel
    Wang, Lu
    Amato, Katherine R.
    Arcila, Maria
    Sos, Martin L.
    Socci, Nicholas D.
    Viale, Agnes
    de Stanchina, Elisa
    Ginsberg, Michelle S.
    Thomas, Roman K.
    Kris, Mark G.
    Inoue, Akira
    Ladanyi, Marc
    Miller, Vincent A.
    Michor, Franziska
    Pao, William
    SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (90)
  • [39] Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib
    Patel, Suchit H.
    Rimner, Andreas
    Foster, Amanda
    Zhang, Zhigang
    Woo, Kaitlin M.
    Yu, Helena A.
    Riely, Gregory J.
    Wu, Abraham J.
    LUNG CANCER, 2017, 108 : 109 - 114
  • [40] Interim Survival Analysis of Gefitinib Plus Vinorelbine in Advanced EGFR-Mutant Non-Small Cell Lung Cancer (Genoa Trial)
    Genova, C.
    Rossi, G.
    Pezzuto, A.
    Valmadre, G.
    Rijavec, E.
    Biello, F.
    Barletta, G.
    Tagliamento, M.
    Dal Bello, M. G.
    Boccardo, S.
    Coco, S.
    Alama, A.
    Sini, C.
    Burrafato, G.
    Maggioni, C.
    Bennicelli, E.
    Cerbone, L.
    Zullo, L.
    Ricci, A.
    Grossi, F.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S829 - S830
12345